The apparent paradox of increased PD-1 expression associated with increased patient survival, when PD-1 is known to be an inhibitor of immune response and seen to be a marker of T-cell terminal differentiation and exhaustion, can be explained by functional adaptation by T-cells with concurrent maintenance of effector function for tumour control and minimal bystander tissue damage [102]. The gene discussed is PDCD1; the disease is neoplasm.